Is there a role for reassessing somatic mutation status at relapse in patients with epithelial ovarian cancer?

No – I don’t think there is any role for reassessment at this point. If commercialization of testing for reversion mutations becomes available – and it will or a functional test of HR status – then yes – I would reassess but I don’t see a reason at this point.

Theoretically yes, however repeat tissue biopsy can be challenging, costly and insurance companies may not reimburse for the repeat genomic testing. Liquid biopsies have improved significantly in the past few years and have a tremendous potential to characterize tumors in a minimally invasive way, h...